Treatment of B-Cell Chronic Lymphocytic Leukemia

Initial Management Approach

The European Society for Medical Oncology recommends a "watch and wait" strategy for early-stage asymptomatic CLL, with regular monitoring of blood counts and clinical examinations every 3 months 2, 3
Treatment should only be initiated when patients develop criteria for "active disease" according to international guidelines 3

The International Workshop on Chronic Lymphocytic Leukemia indicates that B symptoms, such as fever, night sweats, and weight loss, are an indication for treatment 2, 3
Cytopenias not caused by autoimmune phenomena are also an indication for treatment 2, 3
Symptoms or complications from lymphadenopathy, splenomegaly, or hepatomegaly require treatment 2, 6
Progressive lymphocytosis with lymphocyte doubling time <6-12 months is an indication for treatment 3, 4
Autoimmune complications, such as anemia or thrombocytopenia, poorly responsive to corticosteroids, require treatment 3, 5

FISH testing for chromosomal abnormalities, particularly del(17p) and TP53 mutations, is essential for treatment selection, as recommended by the European Society for Medical Oncology 3, 1
Immunoglobulin heavy chain variable region (IGHV) mutational status helps predict treatment response and should be determined before first-line therapy, according to the International Workshop on Chronic Lymphocytic Leukemia 1
Patient fitness assessment, including age, comorbidities, and renal function, guides treatment choice, as indicated by the European Society for Medical Oncology 6, 5

For patients with del(17p) or TP53 mutations, the European Society for Medical Oncology recommends Bruton tyrosine kinase inhibitors (BTKis) such as ibrutinib, acalabrutinib, or zanubrutinib as the preferred first-line options 1
For physically fit patients without del(17p)/TP53 mutations, time-limited therapy with venetoclax (BCL2 inhibitor) plus obinutuzumab for 12 cycles is preferred, especially for patients with mutated IGHV, as recommended by the European Society for Medical Oncology 1
BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) are alternatives, particularly for unmutated IGHV, according to the International Workshop on Chronic Lymphocytic Leukemia 1, 4

If relapse occurs >12-24 months after initial therapy, the first-line treatment may be repeated, as indicated by the International Workshop on Chronic Lymphocytic Leukemia 3, 6
For early relapse (<12 months) or refractory disease, switch to an alternative class of agents, such as a BTK inhibitor or venetoclax-based regimen, as recommended by the European Society for Medical Oncology 1, 3, 6

Regular physical examinations and blood counts to assess response are recommended by the International Workshop on Chronic Lymphocytic Leukemia 2, 3
Bone marrow biopsy only in patients with complete hematologic remission to confirm complete response, as indicated by the European Society for Medical Oncology 7, 3
Imaging (chest X-ray, abdominal ultrasound/CT) if abnormal before therapy, as recommended by the International Workshop on Chronic Lymphocytic Leukemia 2, 3